CRCLE GUAIFENESIN EXTENDED-RELEASE TABLETS, 600 MG- guaifenesin extended-release tablet 
CRCLE GUAIFENSIN EXTENDED RELEASE TABLET, 1200 MG- guaifensin extended-release tablet 
Innovus Pharmaceuticals, Inc.

----------

Guaifenesin Extended-Release Tablets 

Active ingredient 

Guaifenesin 600 mg (for 600 mg)
Guaifenesin 1200 mg (for 1200 mg)

Purpose

Expectorant

Uses

Warnings

Do not use

  • for children under 12 years of age

Ask a doctor before use if you have 

  • persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema
  • cough accompanied by too much phlegm (mucus)

Stop use and ask a doctor if 

cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness.

If pregnant or breast-feeding

 ask a health professional before use.

Keep out of reach of children 

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222)

Directions

Other information

Tamper evident: Do not use if carton is open or if printed seal on blister is broken or missing.

store between 20-25°C (68-77°F)

Inactive ingredients

carbomer homopolymer type B; hypromellose, Lake of FD&C Blue 1, magnesium stearate, microcrystalline cellulose; sodium starch glycolate

Questions?

Contact 1-877-770-3183 Mon-Fri 8:00 AM EST to 5:00 PM PST.

C'rcle Guaifenesin Extended-Release Tablets

600 mg / Expectorant 

100 (20x5) Extended-Release Bi-Layer Tablets

image description

C'rcle Guaifenesin Extended-Release Tablets

1200 mg / Expectorant

56 (14x4) Extended-Release Bi-Layer Tablets

image description

CRCLE GUAIFENESIN EXTENDED-RELEASE TABLETS, 600 MG 
guaifenesin extended-release tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:57483-270
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN600 mg
Inactive Ingredients
Ingredient NameStrength
CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE (UNII: 0A5MM307FC)  
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
HYPROMELLOSES (UNII: 3NXW29V3WO)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
Product Characteristics
Colorblue (white and blue) Scoreno score
ShapeOVALSize16mm
FlavorImprint Code G;600
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:57483-270-015 in 1 CARTON04/28/2023
120 in 1 BLISTER PACK; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA21342009/10/2020
CRCLE GUAIFENSIN EXTENDED RELEASE TABLET, 1200 MG 
guaifensin extended-release tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:57483-280
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN1200 mg
Inactive Ingredients
Ingredient NameStrength
CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE (UNII: 0A5MM307FC)  
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
HYPROMELLOSES (UNII: 3NXW29V3WO)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
Product Characteristics
Colorblue (white-blue) Scoreno score
ShapeOVAL (ellipitcal) Size22mm
FlavorImprint Code G;1200
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:57483-280-024 in 1 CARTON04/28/2023
114 in 1 BLISTER PACK; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA21342009/10/2020
Labeler - Innovus Pharmaceuticals, Inc. (962507187)

Revised: 4/2023
Document Id: 77d8fc95-d94b-42f5-97ae-b5ff59ef638b
Set id: bba4b91a-bea9-41be-9588-5fb1483c7d10
Version: 1
Effective Time: 20230408
 
Innovus Pharmaceuticals, Inc.